explore -WSS

explore

author：entertainment 2025-09-27 12:49:00 - browse：74

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Mindstrong's demise and the future of mental health care

leisure time

Wikipedia

WSS

How the Dana

How corporate America is slashing DEI workers amid backlash to diversity programs

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Biogen shutters digital health group, ends Apple study, in cost cutting move

leisure time

explore

entertainment

In age of alternative facts, a scholarly course on calling out crap

How one patient went off dialysis — and others can too

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Would Medicare drug price negotiations stall in a shutdown?

Cancer drug shortages should be causing more outrage

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Moonlake's readout produced a cash windfall. Risks remain

The PBM ad wars are taking over Washington, D.C.

Medical records are filled with copy

After a drawn out lobbying fight, ARPA

focus

How the Dana

Listen: Who gets the credit for GLP

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

Mindstrong's demise and the future of mental health care

leisure time

Wikipedia

Wikipedia

focus